TUMOR ABLATION MARKET ANALYSIS

Tumor Ablation Market, By Technology (Radiofrequency Ablation, Microwave Ablation, Cryo Ablation, Irreversible Electroporation, Laser Based Thermal Ablation, Other Ablation Technologies), By Treatment (Surgical Ablation, Laparoscopic Ablation, Percutaneous Ablation), By Application (Kidney Cancers, Liver Cancers, Breast Cancers, Lung Cancers, Prostate Cancers, Colorectal Cancers, Other Cancers), By Region (North America, Europem, Asia-Pacific, Middle East, Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Sep 2022
Code : CMI1270
Pages :152
Formats :
Excel and PDF
Industry : Medical Devices

Tumor Ablation MarketSize and Trends

The global tumor ablation market size was valued at USD 1,018.6 million in 2021 and is anticipated to witness a compound annual growth rate (CAGR) of 11.5% from 2022 to 2028. The market is to propel the market as there is an increase in geriatric population, rising cases of cancer or the tumor. Complications linked with the tumor ablation therapy anticipated to hinder the market growth. Based on the segment the market is divided by technology, by treatment, by application.

Figure 1. Global Tumor Ablation Market Share (%), by Region, 2021

Global Tumor Ablation Market Trends:

Lung cancer is one of the main causes of death globally. There are two main forms small cell lung carcinoma and non-small cell lung carcinoma, based on how it takes place under a microscope. Non-small cell lung carcinoma is more usual than small cell lung carcinoma. The rising burden of lung carcinoma owing to rising unhealthy habits, and a surge in R&D actions, combined with the approval of goods, is fueling the market segment's growth.

Rising medical analysis for lung carcinoma and ablation therapy is propelling the segment’s growth. For example, a research survey was introduced in December 2021 by Ethicon Inc. to calculate the efficiency and security of the novel wave-certus microwave ablation method in Chinese patients with initial or secondary cancer in the lung. The survey is anticipated to be finished by December 2024.